Fig. 8
From: EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL
EGR1 enhanced the sensitivity of HCC cells and xenografted tumors to sorafenib. A The IC50 values of sorafenib was detected in PLC/PRF5 and HepG2 cells after EGR1 overexpression. B The ATP levels in HCC cells after EGR1 overexpression, sorafenib treatment and the combinational treatment were detected. C IncuCyte zoom cell proliferation assays were performed to evaluate the combined effect of EGR1 and sorafenib on PLC/PRF5 and HepG2 cells. D The impact of the combination of EGR1 and sorafenib on the capacity of HCC cells to form colonies was examined through colony formation assays. E Xenograft tumor experiments were conducted to assess the influence of AAV-EGR1 in conjunction with sorafenib on the growth of HCC tumors. Tumor dimensions were measured at three-day intervals, and tumor weight was determined upon tumor harvest. **P < 0.01, ***P < 0.001, ****P < 0.0001